Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Betting On The Bancorp, Inc. (TBBK)

Is The Bancorp, Inc. (NASDAQ:TBBK) a buy here? The best stock pickers are getting more optimistic. The number of long hedge fund bets inched up by 5 recently.

In the 21st century investor’s toolkit, there are dozens of metrics shareholders can use to watch stocks. A couple of the most innovative are hedge fund and insider trading interest. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the top fund managers can outclass the S&P 500 by a very impressive amount (see just how much).

Donald YacktmanJust as beneficial, positive insider trading sentiment is another way to parse down the investments you’re interested in. As the old adage goes: there are a number of motivations for an executive to get rid of shares of his or her company, but only one, very obvious reason why they would behave bullishly. Several academic studies have demonstrated the valuable potential of this tactic if piggybackers know what to do (learn more here).

Consequently, let’s take a peek at the key action regarding The Bancorp, Inc. (NASDAQ:TBBK).

What have hedge funds been doing with The Bancorp, Inc. (NASDAQ:TBBK)?

In preparation for this quarter, a total of 12 of the hedge funds we track held long positions in this stock, a change of 71% from the previous quarter. With hedge funds’ positions undergoing their usual ebb and flow, there exists a few key hedge fund managers who were increasing their holdings significantly.

Of the funds we track, Second Curve Capital, managed by Tom Brown, holds the biggest position in The Bancorp, Inc. (NASDAQ:TBBK). Second Curve Capital has a $38.7 million position in the stock, comprising 9.9% of its 13F portfolio. The second largest stake is held by Donald Yacktman of Yacktman Asset Management, with a $33.3 million position; the fund has 0.2% of its 13F portfolio invested in the stock. Some other hedgies that are bullish include Chuck Royce’s Royce & Associates, Michael Price’s MFP Investors and Ken Griffin’s Citadel Investment Group.

As aggregate interest increased, key money managers were breaking ground themselves. Visium Asset Management, managed by Jacob Gottlieb, assembled the largest position in The Bancorp, Inc. (NASDAQ:TBBK). Visium Asset Management had 1.1 million invested in the company at the end of the quarter. Israel Englander’s Millennium Management also made a $0.8 million investment in the stock during the quarter. The other funds with brand new TBBK positions are Jim Simons’s Renaissance Technologies, John Overdeck and David Siegel’s Two Sigma Advisors, and Glenn Russell Dubin’s Highbridge Capital Management.

What do corporate executives and insiders think about The Bancorp, Inc. (NASDAQ:TBBK)?

Insider purchases made by high-level executives is best served when the primary stock in question has experienced transactions within the past half-year. Over the latest 180-day time frame, The Bancorp, Inc. (NASDAQ:TBBK) has experienced 2 unique insiders buying, and zero insider sales (see the details of insider trades here).

With the returns exhibited by Insider Monkey’s research, retail investors should always keep an eye on hedge fund and insider trading sentiment, and The Bancorp, Inc. (NASDAQ:TBBK) shareholders fit into this picture quite nicely.

Click here to learn why you should track hedge funds

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!